Haiquan Fang

This inventor holds 14 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 6 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, The Institute for Pharmaceutical Discovery, LLC. Active years: 2002-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Haiquan Fang. Retrieved from https://idiyas.com/inventor/haiquan-fang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 1)

% Patents Active = 78.6

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 129(Granted Patents)

Location History:

Wallingford, CT (US) (2002 - 2003)
Madison, CT (US) (2008 - 2017)

Company Filing History:

11 out of 3,745

Bristol-Myers Squibb Compnay

patents

3 out of 16

The Institute for Pharmaceutical Discovery, LLC

patents

Years Active: 2002-2017

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9751879 - Tricyclic compounds as anticancer agents (2017-09-05),

2. 9688669 - Oxazolidinones as modulators of mGluR5 (2017-06-27),

3. 9458179 - Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands (2016-10-04),

4. 8481555 - Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs (2013-07-09),

5. 8278320 - Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands (2012-10-02),

6. 7544680 - Constrained compounds as CGRP-receptor antagonists (2009-06-09),

7. 7524878 - Phenyl substituted carboxylic acids (2009-04-28),

8. 7470680 - Constrained compounds as CGRP-receptor antagonists (2008-12-30),

9. 7465825 - Phenyl substituted carboxylic acids (2008-12-16),

10. 7384931 - Constrained compounds as CGRP-receptor antagonists (2008-06-10),

11. 7384930 - Constrained compounds as CGRP-receptor antagonists (2008-06-10),

12. 7329680 - Heterocycle substituted carboxylic acids (2008-02-12),

13. 6573262 - Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives (2003-06-03),

14. 6469006 - Antiviral indoleoxoacetyl piperazine derivatives (2002-10-22),

Title: The Innovative Contributions of Haiquan Fang

Introduction

Haiquan Fang is a renowned inventor based in Madison, CT, who has made significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, Fang has demonstrated a commitment to innovation in developing new therapeutic agents.

Latest Patents

Among his latest patents, Fang has developed a groundbreaking invention titled "Tricyclic Compounds as Anticancer Agents." This invention involves the creation of tricyclic compounds and their pharmaceutically acceptable compositions which are utilized in treating various disorders. Another notable patent is "Oxazolidinones as Modulators of mGluR5," which relates to compounds that act as ligands, agonists, and partial agonists for the mGluR5 receptor. These compounds are expected to be beneficial in addressing various central nervous system disorders.

Career Highlights

Throughout his career, Haiquan Fang has worked for prestigious organizations, including Bristol-Myers Squibb Company and the Institute for Pharmaceutical Discovery, LLC. His experiences in these companies have played a crucial role in shaping his expertise in drug discovery and development.

Collaborations

Fang has collaborated with various professionals to enhance his research and development endeavors. Notable coworkers include Matthew D. Hill and Prasad V. Chaturvedula, with whom he has shared invaluable insights and expertise in the pharmaceutical sciences.

Conclusion

Haiquan Fang's innovative work in pharmaceutical research positions him as a significant contributor to the field. His creative approach to developing new therapeutics aims to address complex health challenges, marking him as an influential figure in the realm of medical inventions.

Profile summary based on public USPTO records.